🇺🇸 FDA
Pipeline program

RO5503781 MBP

NP28679

Phase 1 small_molecule completed

Quick answer

RO5503781 MBP for Myelogenous Leukemia, Acute is a Phase 1 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Myelogenous Leukemia, Acute
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials